

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287
 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Ghoshal, Kaushik (Last) (First) (Middle) RESMED INC. 9001 SPECTRUM CENTER BLVD. (Street) SAN DIEGO CA 92123 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol RESMED INC [RMD] 3. Date of Earliest Transaction (Month/Day/Year) 03/03/2025 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Commercial Officer, SaaS 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct(D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
ResMed Common Stock	03/03/2025		M (1)		367	A	\$211.76	10,092	D	
ResMed Common Stock	03/03/2025		M (1)		3,506	A	\$146.34	13,598	D	
ResMed Common Stock	03/03/2025		M (1)		514	A	\$146.34	14,112	D	
ResMed Common Stock	03/03/2025		M (1)		4,726	A	\$211.76	18,838	D	
ResMed Common Stock	03/03/2025		S (1)		367	D	\$235.2486 (2)	18,471	D	
ResMed Common Stock	03/03/2025		S (1)		3,506	D	\$235.3988 (2)	14,965	D	
ResMed Common Stock	03/03/2025		S (1)		514	D	\$235.2486 (2)	14,451	D	
ResMed Common Stock	03/03/2025		S (1)		4,726	D	\$235.4261 (2)	9,725	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr.3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

ResMed Common Stock Options	\$211.76	03/03/2025		M			367	11/19/2020 (3)	11/19/2027	ResMed Common Stock	367	\$0	105	D	
ResMed Common Stock Options	\$146.34	03/03/2025		M			3,506	11/21/2019 (3)	11/21/2026	ResMed Common Stock	3,506	\$0	3,589	D	
ResMed Common Stock Options	\$146.34	03/03/2025		M			514	11/21/2019 (3)	11/21/2026	ResMed Common Stock	514	\$0	169	D	
ResMed Common Stock Options	\$211.76	03/03/2025		M			4,726	11/19/2020 (3)	11/19/2027	ResMed Common Stock	4,726	\$0	5,882	D	

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024.
2. This transaction was executed in multiple trades at prices ranging from \$235.00 - \$236.18. The price reported above reflects the weighted average sale price.
3. Represents date options first become exercisable. Options vest 1/3 per year.

Kaushik Ghoshal, Chief Commercial Officer, SaaS business

** Signature of Reporting Person

03/04/2025

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

personal